Testosterone transdermal - Elan Pharma

Drug Profile

Testosterone transdermal - Elan Pharma

Latest Information Update: 12 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Pharma International
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 12 Dec 2006 Discontinued - Clinical-Phase-Unknown for Menopausal syndrome in United Kingdom (Transdermal)
  • 24 Jun 1999 Investigation in Menopausal syndrome in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top